9 Myths About Menopause and the End of Sexual Desire That Are Causing Real Harm to Women and Their Partners
So many women quietly grieve the loss of desire and say nothing — not to their doctor, not to their partner, sometimes not even to themselves. The silence around this is part of what makes it so hard to treat. The thing worth knowing is that 'this is just menopause' is almost never the whole story, and the whole story almost always has something useful in it.
Learn more about Rose →Myth: Loss of libido is simply what happens at menopause — it's inevitable
While hormonal shifts do affect sexual desire, significant loss of libido is not a universal or unavoidable outcome of menopause. Large population studies, including the Study of Women's Health Across the Nation (SWAN), found that roughly half of midlife women do not report a clinically meaningful decline in sexual desire. Framing low libido as inevitable discourages women from investigating treatable causes and discourages clinicians from asking the right questions.
Myth: Testosterone has nothing to do with women's desire
Testosterone is the primary hormonal driver of sexual desire in women, just as it is in men — this is well-established in endocrinology. Testosterone levels decline significantly across the reproductive years and drop sharply with surgical menopause, and this decline correlates directly with reduced desire, reduced fantasy, and reduced response to erotic stimuli. Clinical trials of low-dose testosterone therapy in postmenopausal women have shown consistent, statistically significant improvements in desire — yet testosterone remains chronically underprescribed for women.
Myth: If the relationship is good, desire shouldn't disappear
This myth places the burden of low libido on the relationship itself, implying something is wrong with the partnership or the woman's feelings about her partner. In reality, hypoactive sexual desire disorder (HSDD) — the clinical term for distressing low libido — is driven by neurobiological and hormonal factors that operate entirely independently of relationship quality. Women with loving, stable, happy partnerships experience HSDD at the same rates as those with relationship difficulties, because the mechanism is physiological, not relational.
Myth: Vaginal dryness and low libido are the same problem
Vaginal dryness — more precisely described as genitourinary syndrome of menopause (GSM) — and low libido are two distinct conditions with different physiological causes, though they frequently co-occur and each can worsen the other. GSM is caused by declining oestrogen and responds well to local oestrogen or vaginal DHEA; low libido is primarily driven by testosterone decline and central nervous system changes. Treating one does not automatically resolve the other, which is why accurate assessment of both is important.
Myth: Antidepressants prescribed for menopause symptoms won't affect libido
SSRIs and SNRIs are widely prescribed during perimenopause — sometimes for low mood, sometimes off-label for hot flushes — and sexual dysfunction, including low desire, delayed orgasm, and reduced arousal, is one of their most common side effects, affecting an estimated 30–70% of users. This side effect is frequently not discussed at the point of prescription, meaning women who were already experiencing some decline in desire may have it significantly worsened by their treatment without ever connecting the two. Any woman on an antidepressant who notices a change in sexual function should raise it with her prescriber, because alternatives and management strategies exist.
Myth: Low libido in menopause is a psychological problem, not a medical one
This framing has historically sent women to therapy when what they needed was a hormone assessment — and while psychological factors can absolutely influence desire, the primary drivers of menopause-related low libido are biochemical. Declining testosterone, falling oestrogen, disrupted sleep, thyroid dysfunction (which becomes more common in midlife), and chronic pain from undertreated GSM are all physiological contributors that therapy alone cannot address. The evidence-based approach treats the physiology first and adds psychological support where genuinely indicated, not as a substitute for medical investigation.
Myth: Menopausal hormone therapy (MHT) fully restores libido for most women
Standard MHT — oestrogen with or without a progestogen — addresses many menopause symptoms effectively, but its impact on libido is more limited and less consistent than many women hope. MHT can improve libido indirectly by resolving sleep disruption, reducing painful sex from GSM, and improving mood, but it does not replace testosterone, which is the primary hormonal driver of desire. Women who start MHT and still find their libido unresolved are not failing treatment — they may simply need a more complete hormonal assessment that includes androgens.
Myth: Women who lose sexual desire at menopause simply stop wanting sex — their bodies no longer respond physically
Desire and arousal are neurologically distinct processes: desire is the motivation to seek sex, while arousal is the physiological response during it. Some women in menopause report a loss of spontaneous desire — the unprompted urge — while still experiencing responsive desire, meaning arousal and enjoyment when sexual activity begins. Understanding this distinction, which is well-supported in the sexual medicine literature, helps couples and clinicians avoid misreading reduced spontaneous desire as a complete shutdown of sexual function. Responsive desire is entirely normal and does not indicate dysfunction.
Myth: There is nothing clinically proven to help low libido in menopause
This is false, and the persistence of this belief is one of the most harmful myths on this list. Low-dose testosterone therapy has the strongest evidence base, with multiple randomised controlled trials and systematic reviews supporting its efficacy and short-term safety for postmenopausal women with HSDD. Vaginal DHEA (prasterone) has regulatory approval in several countries specifically for sexual dysfunction in menopause. Flibanserin, though licensed only for premenopausal HSDD in the US, represents further evidence that pharmacological pathways for desire exist. The evidence base is not perfect, but it is far stronger than 'nothing works.'
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.